AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm Patch (Active)
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm Patch (Active)
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT Patch (Placebo)
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).
Study NCT03990597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Applied topically
Study NCT01480232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRT Patch (Placebo)
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).
Study NCT01480232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
Study NCT01480232 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
Study NCT01480232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
Study NCT02349204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music - Mozart's sonata for 2 pianos in D-440
Study NCT02918539 — intervention group
Intervention type: DRUG
Intervention: florbetapir F 18 PET scan
Description: For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
Study NCT01461824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Study NCT03990597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03990597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wound Dressing Material
Description: Applied StrataXRT topically
Study NCT00581087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA treatment
Description: DHEA : 200 mg/day hard gelatine capsule
Study NCT00581087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment : 200 mg/day hard gelatine capsule
Study NCT03262038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
Study NCT03262038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
Study NCT01461824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Study NCT03872934 — intervention group
Intervention type: BEHAVIORAL
Intervention: implant anxiety
Description: to determine the type of music that reduces anxiety in patients undergoing implant surgery.
Study NCT04311372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Sesssion+Material+Videos
Description: n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
Study NCT04311372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Sesssion+Material ONLY
Description: n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
Study NCT00985179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
Study NCT04605224 — intervention group
Intervention type: BEHAVIORAL
Intervention: Culinary class
Description: This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
Study NCT01333774 — intervention group
Intervention type: DRUG
Intervention: Glucobay (Acarbose, BAYG5421)
Description: Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study NCT04695236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZOLL Intravascular Temperature Management system, Quattro catheter
Description: ZOLL Intravascular Temperature Management system, Quattro catheter
Study NCT04695236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment for Ischemic Strokre
Study NCT02353689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAP
Description: consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
Study NCT02353689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate FODMAP
Description: consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
Study NCT02353689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high FODMAP
Description: consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
Study NCT04409626 — intervention group
Intervention type: OTHER
Intervention: Plasma sodium level (continuous variables)
Description: Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
Study NCT03140124 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
Study NCT03140124 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Worry Stone
Description: For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
Study NCT04921657 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin 10mg
Study NCT00502619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
Study NCT00502619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
Study NCT02983513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Study NCT03940456 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
Study NCT00520299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG 20
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
Study NCT00136357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: 12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
Study NCT02121314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous administration of 1st line TB drugs, day 1
Description: TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
Study NCT01833806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: Focused Ultrasound Ablation
Study NCT01468038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: active trazodone and sentra pm-like placebo
Study NCT01468038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sentra PM
Description: Active Sentra PM and trazodone-like placebo
Study NCT01468038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sentra PM and Trazodone (CoPack Kit Trazamine)
Description: A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
Study NCT01468038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo trazodone and placebo Sentra PM
Description: Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
Study NCT02724111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufficient dose of rocuronium
Study NCT02724111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 10 min after position change
Study NCT03880006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
Study NCT02757404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasonography guidance injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
Study NCT02757404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrical stimulation guidance injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
Study NCT02757404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manual needle placement injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
Study NCT01526317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
Study NCT01820767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
Study NCT01820767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol, atorvastatin
Description: Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.
Study NCT01820767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
Study NCT02049229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: Optimax-stent implantation
Study NCT02049229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Synergy stent implantation
Study NCT02315105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Greater Curvature Plication
Description: LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
Study NCT01960504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (DREAMS) stenting
Study NCT02802956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Life Promotion Program
Description: Daily Life Promotion Program
Study NCT02802956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general rehabilitation treatment
Description: general rehabilitation treatment
Study NCT03799627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Vadadustat Tablets 150 mg
Study NCT03799627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin Alfa
Study NCT03799627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat TIW
Description: Oral Vadadustat
Study NCT04148768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inferential therapy
Description: Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
Study NCT04148768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short wave diathermy
Description: SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
Study NCT03571113 — intervention group
Intervention type: OTHER
Intervention: Survival / not survival
Description: Outcome with good neurological status vs. bad neurological status at hospital discharge
Study NCT03975530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision Family Spirit
Description: Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
Study NCT03975530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Family Spirit
Description: Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
Study NCT02253472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Study NCT02253472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study NCT02244658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
Study NCT03039569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages
Study NCT00963937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 25 mg
Description: One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Study NCT00963937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 50 mg
Description: Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Study NCT00963937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Study NCT02801396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)
Study NCT04260555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1601
Description: Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
Study NCT04260555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW16011
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
Study NCT02801396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)
Study NCT04260555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW16012
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
Study NCT04597632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brolucizumab
Description: brolucizumab 6 mg/0.05 mL solution for intravitreal injection
Study NCT02938559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy (CT) for depression
Description: There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.